SCHEMBL420909

SCHEMBL420909

COC(=O)c1cc(Cl)ccc1NC(=O)CC(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.56
GAA P10253 2/20 0.52
KDM4E B2RXH2 1/20 0.52
BRD4 O60885 1/20 0.51
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 5/20 0.48
HPGD P15428 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416784 0.87 KDM4E (0.56) NPSR1GAAKDM4EBRD4HTT
SCHEMBL418724 0.84 ALDH1A1 (0.52) NPSR1GAAKDM4EHTTSMN1; SMN2
SCHEMBL1794963 0.83 SERPINE1 (0.52) NPSR1GAAKDM4EHTTSMN1; SMN2
SCHEMBL1798978 0.82 SERPINE1 (0.53) GAAKDM4EHTTSMN1; SMN2ALDH1A1
SCHEMBL4737582 0.80 ALDH1A1 (0.50) NPSR1GAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL1798282 0.80 ALDH1A1 (0.60) NPSR1GAAKDM4EALDH1A1KMT2A
SCHEMBL417874 0.80 RXFP1 (0.54) GAAKDM4EHTTSMN1; SMN2ALDH1A1
SCHEMBL1800967 0.79 CRHBP (0.46) NPSR1GAAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL6510154 0.79 KMT2A (0.63) GAAKDM4ESMN1; SMN2ALDH1A1CYP1A2
SCHEMBL9674267 0.79 ALDH1A1 (0.65) GAAKDM4EHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 NPSR1 3219/4885GAA 812/4885KDM4E 4490/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 NPSR1 3219/4885GAA 812/4885KDM4E 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.